USPTO serial 79411026
SYGNATURE DISCOVERY
Reviewed by CopyMark Law Group
Status 402
- Filing date
- Status date
- Registration date
- —
- Examiner
- MARSH, LAURA KATHLEEN
- Law office
- TMEG LAW OFFICE 107
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with SYGNATURE DISCOVERY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Proteins for use in industry; proteins for use in manufacture; proteins for use in science; proteins for use in the manufacture of pharmaceutical products; raw proteins; raw proteins for use in industry; raw proteins for use in manufacture; raw proteins for use in science; raw proteins for use in the manufacture of pharmaceutical products. | SECTION 70 - CANCELLED | — |
| 040 | Processing of organic chemical liquids; recycling of organic solvents; purification of proteins; purification of proteins by chemical methods. | SECTION 70 - CANCELLED | — |
| 042 | Scientific research and development services; drug discovery services; development of pharmaceutical preparations and medicines; drug screening for scientific purposes; pharmaceutical drug development services; research and development of vaccines and medicines; research and development of drugs; research relating to medicines; services for assessing the efficacy of drugs; conducting early evaluations in the field of new pharmaceuticals; consultancy in the field of pharmaceutical research; consultancy relating to pharmaceutical research and developments; development of pharmaceutical preparations and medicines; inspection of pharmaceuticals; laboratory research services relating to pharmaceuticals; pharmaceutical drug development services; pharmaceutical product evaluation; pharmaceutical research and development; proving medical and scientific research information in the field of pharmaceuticals and drug development; research and development in the pharmaceutical and drug development fields; testing of pharmaceutical drugs; assay development services; biological research; biological analysis; biological development services; biological laboratory services; biological research, clinical research and medical research; consultancy relating to pharmacology; medical and pharmacological research services; scientific research for medical purposes; research in the field of synthetic biology; research and development in the field of microorganisms and cells; chemical research and analysis services; chemical engineering; chemistry services; medicinal, synthetic, analytical and high throughput chemistry services; clinical research; organic chemistry research and analysis services; consultancy in the field of organic chemistry; laboratory research and analysis services in the field of organic chemistry; research and development services in the field of organic chemistry; development, testing and analysis of chemicals; development, testing and analysis of chemical production methods; protein and peptide mapping for scientific purposes; scientific analysis services; protein analysis services for scientific purposes; protein sequencing research; protein crystallisation screening for scientific purposes; quality control; testing of materials; testing of products; technological research; industrial analysis and research services; scientific services relating to cell line generation; scientific screening services; compound profiling and selectivity services; X-ray imaging, other than for medical purposes; blood analysis services; blood analysis services for scientific research purposes; information, advisory and consultancy services relating to the aforesaid services. | SECTION 70 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 6, 2026 | IROP | IRREGULARITY ON NOTICE OF POSSIBLE OPPOSITION RECEIVED FROM IB | — |
| Apr 27, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 27, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Nov 30, 2025 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Nov 6, 2025 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Nov 6, 2025 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| May 9, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 24, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 24, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 14, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 13, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 12, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 29, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 29, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 28, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |